Synapse - Howard Scher

Search Within

Howard Scher

Results (159)

Circulating tumor cell (CTC) number as a response endpoint in metastatic castration resistant (mCRPC) compared with PSA across five randomized phase 3 trials

Meeting Abstract

Heller, G.; McCornnack, R. T.; Kheoh, T.; Smith, M. R.; Dreicer, R.; Saad, F.; De Wit, R.; Aftab, D. T.; Hirmand, M.; MacLean, D. B.; more...
Journal of Clinical Oncology (2017)

Fulltext@MSK | Save

Translating prostate cancer working group (PCWG) criteria into a quantitative progression biomarker in metastatic castration resistant prostate cancer (mCRPC)

Meeting Abstract

Anand, A.; Heller, G.; Scher, H. I.; Morris, M. J.
Journal of Clinical Oncology (2017)

Fulltext@MSK | Save

Phenotypic heterogeneity of circulating tumor cells informs clinical decisions between AR signaling inhibitors and taxanes in metastatic prostate cancer

Journal Article

Scher, H. I.; Graf, R. P.; Schreiber, N. A.; McLaughlin, B.; Jendrisak, A.; Wang, Y.; Lee, J.; Greene, S.; Krupa, R.; Lu, D.; more...
Cancer Research (2017)

Fulltext@MSK | Save

A pilot study of a multimodal treatment paradigm to accelerate drug evaluations in early-stage metastatic prostate cancer

Journal Article

O'Shaughnessy, M. J.; McBride, S. M.; Vargas, H. A.; Touijer, K. A.; Morris, M. J.; Danila, D. C.; Laudone, V. P.; Bochner, B. H.; Sheinfeld, J.; Dayan, E. S.; more...
Urology (2017)

Fulltext@MSK | Save

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients

Journal Article

Zehir, A.; Benayed, R.; Shah, R. H.; Syed, A.; Middha, S.; Kim, H. R.; Srinivasan, P.; Gao, J.; Chakravarty, D.; Devlin, S. M.; more...
Nature Medicine (2017)

Fulltext@MSK | Save

Nuclear-specific AR-V7 protein localization is necessary to guide treatment selection in metastatic castration-resistant prostate cancer

Journal Article

Scher, H. I.; Graf, R. P.; Schreiber, N. A.; McLaughlin, B.; Lu, D.; Louw, J.; Danila, D. C.; Dugan, L.; Johnson, A.; Heller, G.; more...
European Urology (2017)

Fulltext@MSK | Save

The added value of circulating tumor cell enumeration to standard markers in assessing prognosis in a metastatic castration-resistant prostate cancer population

Journal Article

Heller, G.; Fizazi, K.; McCormack, R.; Molina, A.; MacLean, D.; Webb, I. J.; Saad, F.; De Bono, J. S.; Scher, H. I.
Clinical Cancer Research (2017)

Fulltext@MSK | Save

Impact of AR-V7 protein localization in the prediction of therapeutic benefit of taxanes over androgen receptor signaling inhibitors (ARSi) in metastatic castration resistant prostate cancer (mCRPC)

Meeting Abstract

Scher, H.; Graf, R.; Schreiber, N.; Lu, D.; Louw, J.; Alvarez, H. A. V.; Bambury, R.; Danila, D.; McLaughlin, B.; Heller, G.; more...
Annals of Oncology (2016)

Fulltext@MSK | Save

Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer

Journal Article

Scher, H. I.; Lu, D.; Schreiber, N. A.; Louw, J.; Graf, R. P.; Vargas, H. A.; Johnson, A.; Jendrisak, A.; Bambury, R.; Danila, D.; more...
JAMA Oncology (2016)

Fulltext@MSK | Save

First-in-human imaging with (89)Zr-Df-IAB2M Anti-PSMA minibody in patients with metastatic prostate cancer: Pharmacokinetics, biodistribution, dosimetry, and lesion uptake

Journal Article

Pandit-Taskar, N.; O'Donoghue, J. A.; Ruan, S.; Lyashchenko, S. K.; Carrasquillo, J. A.; Heller, G.; Martinez, D. F.; Cheal, S. M.; Lewis, J. S.; Fleisher, M.; more...
Journal of Nuclear Medicine (2016)

Fulltext@MSK | Save